The Functional Dyspepsia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Functional Dyspepsia pipeline products will significantly revolutionize the Functional Dyspepsia market dynamics. 

Functional Dyspepsia Overview 

Functional Dyspepsia (FD) is a term for recurring signs and symptoms of indigestion that have no obvious cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. 

The etiology of functional dyspepsia is likely heterogeneous and multifactorial; however, the exact cause is not clearly understood. Several risk factors have been seen to be associated with the condition like, enteric infections, recent use of antibiotics and non-steroidal anti-inflammatory drugs, overweight, smoking, psychosocial dysfunction and others. Functional dyspepsia comprises three subtypes with presumed different pathophysiology and etiology: postprandial distress syndrome (PDS), epi-gastric pain syndrome (EPS) and a subtype with overlapping PDS and EPS features. 

Some of the key facts of the Functional Dyspepsia Market Report: 

• The Functional Dyspepsia market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
• According to the study conducted by Talley, Functional dyspepsia affects 10% of the population and is more prevalent in women 
• According to AC et al., approximately 80% of individuals with dyspepsia have no structural explanation for their symptoms and have functional dyspepsia 
• Key Functional Dyspepsia Companies: Takeda, Xian-Janssen Pharmaceutical Ltd., Zeria Pharmaceutical Co., Ltd, Astellas Pharma Inc., Daewoong Pharmaceutical Co. LTD., and others 
• Key Functional Dyspepsia Therapies: Vonoprazan (TAK-438), Domperidone, Z-338, YM443, Acotiamide hydrochloride hydrate, and others 
• The Functional Dyspepsia epidemiology based on gender analyzed that Functional Dyspepsia affects females more than males

Get a Free sample for the Functional Dyspepsia Market Report 

Key benefits of the Functional Dyspepsia Market report:

1. Functional Dyspepsia market report covers a descriptive overview and comprehensive insight of the Functional Dyspepsia Epidemiology and Functional Dyspepsia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Functional Dyspepsia market report provides insights on the current and emerging therapies.
3. Functional Dyspepsia market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Functional Dyspepsia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Functional Dyspepsia market.

Discover more about therapies set to grab major Functional Dyspepsia market share @ Functional Dyspepsia market forecast 

Functional Dyspepsia Epidemiology Segmentation:

The Functional Dyspepsia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Functional Dyspepsia
• Prevalent Cases of Functional Dyspepsia by severity
• Gender-specific Prevalence of Functional Dyspepsia
• Diagnosed Cases of Episodic and Chronic Functional Dyspepsia 

Functional Dyspepsia Market  

The dynamics of the Functional Dyspepsia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

Download the report to understand which factors are driving Functional Dyspepsia epidemiology trends @ Functional Dyspepsia Epidemiological Insights

Functional Dyspepsia Therapies and Key Companies

• Acofide: Zeria Pharmaceutical
• Rikkunshito: Tsumura and Company, Tokyo 

Scope of the Functional Dyspepsia Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Functional Dyspepsia Companies: Takeda, Xian-Janssen Pharmaceutical Ltd., Zeria Pharmaceutical Co., Ltd, Astellas Pharma Inc., Daewoong Pharmaceutical Co. LTD., and others
• Key Functional Dyspepsia Therapies: Vonoprazan (TAK-438), Domperidone, Z-338, YM443, Acotiamide hydrochloride hydrate, and others
• Functional Dyspepsia Therapeutic Assessment: Functional Dyspepsia current marketed and Functional Dyspepsia emerging therapies
• Functional Dyspepsia Market Dynamics:  Functional Dyspepsia market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Functional Dyspepsia  Market Access and Reimbursement

Table of Contents 

1. Functional Dyspepsia Market Report Introduction

2. Executive Summary for Functional Dyspepsia

3. SWOT analysis of Functional Dyspepsia

4. Functional Dyspepsia Patient Share (%) Overview at a Glance

5. Functional Dyspepsia Market Overview at a Glance

6. Functional Dyspepsia Disease Background and Overview

7. Functional Dyspepsia Epidemiology and Patient Population

8. Country-Specific Patient Population of Functional Dyspepsia 

9. Functional Dyspepsia Current Treatment and Medical Practices

10. Functional Dyspepsia Unmet Needs

11. Functional Dyspepsia Emerging Therapies

12. Functional Dyspepsia Market Outlook

13. Country-Wise Functional Dyspepsia Market Analysis (2019–2032)

14. Functional Dyspepsia Market Access and Reimbursement of Therapies

15. Functional Dyspepsia Market drivers

16. Functional Dyspepsia Market barriers

17.  Functional Dyspepsia Appendix

18. Functional Dyspepsia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Functional Dyspepsia treatment, visit @ Functional Dyspepsia Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/